If you’ve noticed that your thinking has slowed, your motivation has gone flat, or words that used to come easily now take a moment, you’re dealing with real brain chemistry. The brain changes with age in ways that standard bloodwork rarely catches.
Citicoline, also called CDP choline, directly supports three things that decline as the brain ages: acetylcholine production, the phospholipid integrity of neuronal cell membranes, and the metabolic energy available to the frontal lobe. The research on all three is solid.
Clinical trials go back to the 1970s. The safety record was built on decades of prescription use in Europe. Here is what those studies actually show.
Table of Contents
What is citicoline (CDP choline)?
Citicoline is a naturally occurring compound found in every cell in the body, with the highest concentrations in brain cells. It builds and repairs the membranes that protect neurons and provides the raw material for acetylcholine synthesis. A separate effect documented by brain imaging is its impact on frontal lobe energy metabolism.
You may see it called CDP choline, cytidine diphosphate choline, or by the branded name Cognizin. All three refer to the same molecule. Cognizin is a form developed by Kyowa Hakko Bio and used in many of the peer-reviewed human trials discussed in this article.
Citicoline is found in some foods, mainly organ meats, but not in amounts that produce cognitive effects. When you take a supplement, it breaks down in the gut into choline and cytidine. Both cross the blood-brain barrier, where the brain reassembles them into citicoline. This matters because plain choline supplements don’t cross the blood-brain barrier as efficiently. The cytidine component has its own role too: it supports nucleotide synthesis and mitochondrial function once inside.1
Six citicoline benefits supported by research
1. Citicoline supports acetylcholine production and dopamine pathways
Acetylcholine is the neurotransmitter most directly tied to memory. It converts short-term experiences into long-term ones and drives sustained attention. Citicoline is a direct biosynthetic precursor to acetylcholine: it supplies the choline that neurons need to synthesize it.1 That’s established biochemistry. As acetylcholine declines with age, so does the ability to form and retrieve memories. Citicoline addresses this at the source.
The dopamine picture is more nuanced. In animal research, chronic CDP-choline treatment increased striatal dopamine receptor density by 11–18%.2 That specific mechanism hasn’t been directly measured in humans using the same imaging methods. What human trials do show is the downstream picture: significantly reduced cocaine cravings in a controlled trial, improved attention and psychomotor speed in a randomized study, and better motivational outcomes in patients with cognitive decline. The behavioral evidence is consistent with what the preclinical data would predict.
One clinical note worth knowing: many common medications are anticholinergic, meaning they actively block acetylcholine. This includes over-the-counter antihistamines like diphenhydramine (Benadryl) and many antidepressants. If you’re taking any of these regularly, your acetylcholine levels may be lower than you realize.
Best for:
- Memory consolidation: converting short-term to long-term memories
- Motivation and goal-directed behavior
- Counteracting acetylcholine depletion from anticholinergic medications
- Attention and focus support: backed by human trials
2. Citicoline supports brain energy metabolism
The brain uses 20% of the body’s total energy while being roughly 2% of body weight. It runs on glucose, can’t store meaningful reserves, and depends entirely on mitochondrial function and blood flow to keep the supply constant.
A 2008 study from McLean Hospital at Harvard Medical School used phosphorus magnetic resonance spectroscopy (31P-MRS) to image frontal lobe metabolic activity before and after 6 weeks of Cognizin supplementation in healthy adults. The result: significantly increased phosphocreatine and beta-NTP (ATP) in the frontal lobe, along with increases in phosphocholine and phosphoethanolamine.3 In plain terms: after 6 weeks, brain cells in the frontal lobe were producing and holding more energy. These are direct measures of cellular energy, not theoretical estimates.
Why does the frontal lobe matter? It’s the region responsible for planning, working memory, sustained attention, and decision-making. When it’s running low on energy, you notice it: mental fatigue, trouble concentrating, slower thinking. This study documents that citicoline improves those energy reserves in living human brains.
Citicoline also supports cerebral blood flow,1 which matters because even modest reductions in circulation to the brain produce noticeable cognitive effects. European physicians have prescribed citicoline for cerebrovascular indications for decades.
Best for:
- Mental fatigue and difficulty sustaining focus
- Working memory and executive function
- Brain energy metabolism: directly measured in humans using spectroscopy
- Age-related reduction in cerebral blood flow
CDP Choline by Doctor’s Nutrition
Each capsule contains 250 mg of Cognizin, the same branded form of citicoline used in the Harvard/McLean Hospital brain energy research and other peer-reviewed human trials cited in this article. Cognizin is different from a basic choline supplement because it delivers both choline and cytidine, the two components the brain uses to synthesize citicoline and build phospholipid membranes.
3. Citicoline protects and rebuilds brain cell membranes
Every neuron is enclosed by a phospholipid membrane that regulates what enters and exits the cell. Nutrients and signaling molecules get in. Toxins and metabolic waste get filtered out. When these membranes degrade, cell signaling fails and neurons become vulnerable.
Citicoline is a direct precursor to phosphatidylcholine, the primary structural phospholipid in neuronal cell membranes.4 It provides the raw material for building and repairing those membranes. That’s well-established biochemistry. A greater availability of citicoline means faster membrane repair after the damage that accumulates from aging, environmental toxins, or acute injury.
This membrane-stabilizing effect is why citicoline has been studied in stroke recovery. Stroke triggers a rapid cascade of membrane destruction through phospholipase activation and free radical production. Citicoline slows that cascade and supports reconstruction. It’s one of the most logical applications in the entire pharmacology.
Best for:
- Neuronal membrane repair after aging or injury
- Phosphatidylcholine synthesis: the structural backbone of brain cells
- Neuroprotection in cerebrovascular events (studied in stroke)
4. Citicoline slows brain cell aging
Two processes do more damage to the aging brain than most others: oxidative stress and chronic low-grade inflammation. Citicoline works against both.
The brain is uniquely vulnerable to oxidative damage because of its high oxygen demand. Free radicals, generated as a byproduct of energy metabolism, attack cell membranes, mitochondria, and DNA continuously. The brain doesn’t have strong built-in antioxidant defenses on its own.
Citicoline supports glutathione synthesis and augments glutathione reductase activity, two effects that strengthen the brain’s endogenous antioxidant system.4 It also maintains mitochondrial cardiolipin levels, a phospholipid essential for the structural integrity of the mitochondrial membrane and for efficient ATP production. These are preclinical findings, but the mechanism is well-characterized and consistent with citicoline’s broader phospholipid activity.
A 2020 systematic review on citicoline in neurological disorders identified anti-inflammatory activity as a distinct mechanism of action, separate from its membrane and energy effects.6 Subclinical brain inflammation is associated with Alzheimer’s disease, Parkinson’s disease, depression, and faster cognitive decline. Suppressing it is a meaningful long-term goal.
Best for:
- Antioxidant support: via glutathione pathway
- Mitochondrial membrane integrity and energy efficiency
- Reducing subclinical brain inflammation over time
- Long-term neuroprotection in aging populations
5. Citicoline and neurological conditions
Citicoline has been studied in some of the most demanding clinical situations in neurology: age-related memory loss, mild cognitive impairment, Alzheimer’s disease, stroke, traumatic brain injury, and glaucoma.
For memory and early cognitive decline, the evidence is genuinely encouraging. A 2023 systematic review and meta-analysis of 7 controlled studies found consistent improvements in cognitive status across all included studies, with pooled effect sizes ranging from 0.56 to 1.57.7 A consistent signal across 7 independent studies is clinically meaningful. The authors called for larger and higher-quality trials, which is standard practice, but the direction of the evidence is clear. A 2021 randomized, double-blind, placebo-controlled trial in healthy older adults with age-associated memory impairment found that 12 weeks of citicoline significantly improved episodic memory.8
Stroke is where the evidence is most mixed, and it deserves an honest framing. The 2020 Cochrane review concluded that citicoline may make little to no difference in major stroke outcomes including mortality, disability, and functional recovery, based on low-certainty evidence.9 A 2025 network meta-analysis found more favorable signals at 500 mg and 2,000 mg doses.10 The stroke evidence remains contested. What’s more established is the underlying mechanism: membrane stabilization during the inflammatory cascade that follows a stroke. That biology is sound regardless of where the outcomes data ultimately lands.
In glaucoma, a line of research suggests citicoline may support retinal ganglion cell health. Studies are primarily from European trials and the evidence base needs larger confirmation.
Best for:
- Age-associated memory impairment: consistent positive signal in 7 controlled studies
- Episodic memory: significant improvement in a 2021 RCT
- Neuroprotection after acute brain injury (stroke, TBI): via membrane stabilization
- Glaucoma: preliminary research on retinal ganglion cell health
6. Citicoline and mental health
Citicoline’s effects on dopamine pathways extend into behavioral and psychiatric territory, and the human evidence here is more direct than in some other areas.
A 2011 double-blind, placebo-controlled trial in cocaine-dependent volunteers found that daily citicoline significantly reduced cocaine use.11 Citicoline appears to work by supporting dopamine pathway function and by repairing the phospholipid membrane damage that chronic cocaine use causes.
For attention and cognitive speed, a 2015 randomized trial in 75 healthy adolescent males found that 28 days of Cognizin improved attention (p = 0.02) and psychomotor speed (p = 0.03) compared to placebo.12 The subjects had no ADHD diagnosis. A 2024 pilot study in pediatric ADHD specifically reported preliminary safety and possible benefit13, a promising early signal, though not yet a confirmed clinical finding.
Citicoline also changes how the brain processes food-related cues. Imaging research found that it altered cortico-limbic activation in response to high-calorie food images, reducing the reward response.14 This has implications for appetite regulation and compulsive eating patterns.
Best for:
- Addiction support: reduced cocaine use in a double-blind RCT
- Attention and processing speed: improved in a 28-day randomized trial
- Appetite and food-cue reactivity: via cortico-limbic modulation
- ADHD: early-stage research, not yet a confirmed clinical application
Citicoline dosage and safety
Most of the cognitive and memory research used 250–500 mg per day. The 2008 Harvard/McLean brain energy study measured effects at both 500 mg and 2,000 mg.3 Higher doses have been used in acute neurological contexts like stroke and TBI.
Citicoline is well-tolerated. Side effects are uncommon and mild when they do occur: occasional headache, digestive discomfort, or sleep disruption if taken late in the day. No serious adverse events have been documented in clinical trials at therapeutic doses. It’s not habit-forming and doesn’t produce tolerance.
On the question of whether citicoline is banned: it isn’t. In the United States and most of Europe, it’s available over the counter as a dietary supplement. In several European countries, it’s also a prescription medication for stroke and cognitive impairment. That dual status is what generates confusion online.
Frequently asked questions
Is citicoline the same as CDP choline?
Yes. Citicoline, CDP choline, and cytidine diphosphate choline are the same compound. Cognizin is a branded form used in peer-reviewed human studies. All three names refer to the same molecule.
What is Cognizin citicoline?
Cognizin is a branded form of citicoline developed by Kyowa Hakko Bio. It’s the form used in most of the peer-reviewed human trials discussed in this article, including the Harvard/McLean Hospital brain energy study and the randomized trials on memory, attention, and psychomotor speed.
Cognizin is the same molecule as citicoline, produced under controlled manufacturing standards. Researchers use it in controlled trials because the standardization makes results reproducible. DN CDP Choline uses 250 mg of Cognizin per capsule because it’s the form with the strongest human research behind it.
Does citicoline increase dopamine?
Preclinical research in aged mice documents an 11–18% increase in striatal dopamine receptor density with chronic CDP-choline treatment.2 Directly measuring dopamine changes in humans requires specialized imaging that isn’t typically included in supplement trials, so that specific receptor-level effect hasn’t been confirmed in people by the same method. What human trials do show is consistent with dopamine activity: a 2011 RCT found significantly reduced cocaine cravings11 and a 2015 RCT found improved attention and psychomotor speed in healthy males.12 The preclinical mechanism is well-characterized; the behavioral evidence in humans lines up with it.
How does citicoline compare to alpha-GPC?
Both compounds raise acetylcholine levels. Alpha-GPC delivers a higher choline percentage by weight and is often the preference for acute acetylcholine support. Citicoline has a broader research base, adds the cytidine component for membrane synthesis, and has a longer clinical history for neuroprotection. They’re not mutually exclusive; some practitioners use both depending on the clinical goal.
What is the recommended citicoline dosage?
Most studies supporting memory and cognitive benefits used 250–500 mg per day. DN CDP Choline contains 250 mg of Cognizin per capsule, taken once daily. Higher doses have been used in neurological research under clinical supervision.
Is citicoline safe for long-term use?
Decades of prescription use in Europe for stroke and cognitive impairment have not identified serious safety concerns. Clinical trials confirm a favorable profile. Citicoline is not habit-forming and doesn’t lose effectiveness with continued use.
Can citicoline help with ADHD?
The research is early but promising. A 2015 RCT in healthy adolescent males showed significant improvements in attention and psychomotor speed.12 A 2024 pilot study in pediatric ADHD reported preliminary safety and possible benefit.13 These are encouraging signals, not confirmed treatment evidence. Anyone using citicoline for attention disorders should do so with a healthcare provider who can assess the full clinical picture.
Ready to know where you actually stand?
This article gives you the research. What it can’t give you is your own clinical picture: whether your acetylcholine is low, whether your cerebral blood flow is reduced, or whether there’s a different driver behind your cognitive symptoms. At Doctor’s Nutrition, we run the labs first. Consultations are always free. You’ll leave with a clear sense of where you stand and what’s worth doing for your specific situation. No obligation, no sales pitch. Just answers. Schedule your free consultation →
References
1. Secades, Julio J., and Pietro Gareri. “Citicoline: Pharmacological and Clinical Review, 2022 Update.” Revista de Neurología 75, Supl. 5 (2022): S1–S89. DOI: 10.33588/rn.75S05.2022311. PMID: 36544369.
2. Giménez, R., J. Raïch, and J. Aguilar. “Changes in Brain Striatum Dopamine and Acetylcholine Receptors Induced by Chronic CDP-Choline Treatment of Aging Mice.” British Journal of Pharmacology 104, no. 3 (1991): 575–578. DOI: 10.1111/j.1476-5381.1991.tb12471.x. PMID: 1839138. PMCID: PMC1908237.
3. Silveri, M. M., J. Dikan, A. J. Ross, J. E. Jensen, T. Kamiya, Y. Kawada, P. F. Renshaw, and D. A. Yurgelun-Todd. “Citicoline Enhances Frontal Lobe Bioenergetics as Measured by Phosphorus Magnetic Resonance Spectroscopy.” NMR in Biomedicine 21, no. 10 (2008): 1066–1075. DOI: 10.1002/nbm.1281. PMID: 18816480.
4. Adibhatla, Rao Muralikrishna, and J. F. Hatcher. “Cytidine 5′-Diphosphocholine (CDP-Choline) in Stroke and Other CNS Disorders.” Neurochemical Research 30, no. 1 (2005): 15–23. DOI: 10.1007/s11064-004-9681-8. PMID: 15756928. PMCID: PMC1934404.
5. See Reference 4. Glutathione synthesis and mitochondrial cardiolipin effects are preclinical neuroprotective mechanisms reviewed in Adibhatla and Hatcher (2005).
6. Jasielski, P., F. Piędel, M. Piwek, A. Rocka, V. Petit, and K. Rejdak. “Application of Citicoline in Neurological Disorders: A Systematic Review.” Nutrients 12, no. 10 (2020): 3113. DOI: 10.3390/nu12103113. PMID: 33053828. PMCID: PMC7601330.
7. Bonvicini, M., S. Travaglini, D. Lelli, R. Antonelli Incalzi, and C. Pedone. “Is Citicoline Effective in Preventing and Slowing Down Dementia? A Systematic Review and a Meta-Analysis.” Nutrients 15, no. 2 (2023): 386. DOI: 10.3390/nu15020386. PMID: 36678257. PMCID: PMC9866349.
8. Nakazaki, E., E. Mah, K. D. Sanoshy, D. Citrolo, and F. Watanabe. “Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.” Journal of Nutrition 151, no. 8 (2021): 2153–2160. DOI: 10.1093/jn/nxab119. PMID: 33978188. PMCID: PMC8349115.
9. Martí-Carvajal, A. J., C. Valli, C. E. Martí-Amarista, I. Solà, J. Martí-Fàbregas, and X. Bonfill Cosp. “Citicoline for Treating People With Acute Ischemic Stroke.” Cochrane Database of Systematic Reviews (2020). DOI: 10.1002/14651858.CD013066.pub2. PMID: 32860632.
10. Zhao, X., X. Huo, et al. “The Efficacy of Different Doses of Citicoline in Improving the Prognosis of Patients With Acute Ischemic Stroke Based on Network Meta-Analysis.” Frontiers in Pharmacology (2025). DOI: 10.3389/fphar.2025.1529647. PMID: 40255575. PMCID: PMC12006040.
11. Licata, S. C., D. M. Penetar, C. Ravichandran, J. Rodolico, C. Palmer, J. Berko, T. Geaghan, A. Looby, E. Peters, E. Ryan, P. F. Renshaw, and S. E. Lukas. “Effects of Daily Treatment With Citicoline: A Double-Blind, Placebo-Controlled Study in Cocaine-Dependent Volunteers.” Journal of Addiction Medicine 5, no. 1 (2011): 57–64. PMID: 21769048. PMCID: PMC3140015.
12. McGlade, E., A. M. Agoston, J. DiMuzio, M. Kizaki, E. Nakazaki, T. Kamiya, and D. Yurgelun-Todd. “The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males.” Journal of Attention Disorders 23, no. 2 (2019): 121–134. DOI: 10.1177/1087054715593633. PMID: 26179181.
13. Hübner, I. B., D. B. Scheibe, J. Marchezan, and J. Bücker. “Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.” Clinical Neuropharmacology 47, no. 4 (2024): 146–149. DOI: 10.1097/WNF.0000000000000602. PMID: 38976279.
14. Killgore, W. D. S., A. J. Ross, T. Kamiya, Y. Kawada, P. F. Renshaw, and D. A. Yurgelun-Todd. “Citicoline Affects Appetite and Cortico-Limbic Responses to Images of High-Calorie Foods.” International Journal of Eating Disorders 43, no. 1 (2009): 6–13. DOI: 10.1002/eat.20658. PMID: 19260039. PMCID: PMC3378241.duces drug cravings in cocaine addicts. It helps repair brain cell membranes damaged by cocaine use.
